JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Extending ketamine's antidepressant effects.

Kenji Hashimoto

Science (New York, N.Y.) May 8, 2025 DOI: 10.1126/science.adx4559 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Preclinical study Peer reviewed
Population	Animal models
Intervention	ketamine
Topics	Depression Ketamine Esketamine
Keywords	Mental health Pharmacology
Citations	9
Key points	Boosting the mTOR signaling pathway preserves the antidepressant response to ketamine.

Abstract

Boosting an intracellular signaling pathway preserves the antidepressant response to ketamine.

Comparable studies

Other preclinical and animal studies on ketamine for depression, most cited first.

Study	Year	Design	Participants
Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression Rats	2020	Preclinical study
Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model Susceptible mice after chronic social defeat stress	2017	Preclinical animal study
Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression Susceptible mice in the social defeat stress model	2016	Animal experimental study
Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression Wistar-Kyoto (WKY) rats and Wistar control rats	2020	Preclinical study
Effect of Ketamine on LTP and NMDAR EPSC in Hippocampus of the Chronic Social Defeat Stress Mice Model of Depression Male C57BL/6J mice	2018	Controlled laboratory experiment

Explore topics

Depression Ketamine Esketamine

By condition and practice

Ketamine for depression